Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-221: Domvanalimab, Zimberelimab, and Chemotherapy vs Nivolumab and Chemotherapy in Advanced Upper GI Adenocarcinoma
NCT05568095Phase 3Completed
- Sponsor
- Arcus Biosciences
- Start
- Nov 2022
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of domvanalimab, zimberelimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Arcus Biosciences. Started Nov 2022; status: completed.
02
Drugs
domvanalimabzimberelimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT05568095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568095.